Point72 Asset Management’s Biogen BIIB Stock Holding History

Point72 Asset Management’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$148M	Sell	809,617 -2,003,575	-71%	-$369M	0.19%	97
2025 Q4	$495M	Sell	2,813,192 -1,059,709	-27%	-$173M	0.55%	18
2025 Q3	$543M	Buy	3,872,901 +41,174	+1%	+$5.57M	0.91%	11
2025 Q2	$481M	Buy	3,831,727 +3,424,470	+841%	+$427M	0.94%	8
2025 Q1	$55.7M	Buy	+407,257	New	+$58.2M	0.13%	195
2023 Q4	–	Sell	-48,100	Closed	-$12.4M	–	2184
2023 Q3	$12.4M	Sell	48,100 -577,541	-92%	-$154M	0.04%	570
2023 Q2	$178M	Sell	625,641 -69,472	-10%	-$20.7M	0.53%	25
2023 Q1	$193M	Sell	695,113 -531,011	-43%	-$147M	0.6%	19
2022 Q4	$340M	Sell	1,226,124 -451,858	-27%	-$128M	1.15%	7
2022 Q3	$448M	Buy	1,677,982 +1,222,182	+268%	+$260M	1.79%	1
2022 Q2	$93M	Buy	455,800 +360,000	+376%	+$73.6M	0.39%	52
2022 Q1	$20.2M	Sell	95,800 -515,700	-84%	-$112M	0.08%	326
2021 Q4	$147M	Buy	611,500 +580,648	+1,882%	+$149M	0.59%	14
2021 Q3	$8.73M	Sell	30,852 -214,654	-87%	-$70.4M	0.04%	525
2021 Q2	$85M	Buy	245,506 +130,106	+113%	+$39.4M	0.38%	47
2021 Q1	$32.3M	Sell	115,400 -83,360	-42%	-$22.5M	0.15%	182
2020 Q4	$48.7M	Buy	198,760 +82,817	+71%	+$21.4M	0.24%	100
2020 Q3	$32.9M	Buy	+115,943	New	+$32.3M	0.17%	170
2020 Q1	–	Sell	-54,081	Closed	-$16.4M	–	783
2019 Q4	$16M	Buy	+54,081	New	+$15M	0.08%	294
2019 Q1	–	Sell	-35,000	Closed	-$10.5M	–	1027
2018 Q4	$10.5M	Sell	35,000 -7,500	-18%	-$2.39M	0.05%	405
2018 Q3	$15M	Sell	42,500 -103,500	-71%	-$35.6M	0.06%	370
2018 Q2	$42.4M	Sell	146,000 -298,615	-67%	-$84M	0.17%	167
2018 Q1	$122M	Buy	444,615 +192,296	+76%	+$59.7M	0.51%	38
2017 Q4	$80.4M	Sell	252,319 -255,603	-50%	-$82M	0.35%	69
2017 Q3	$159M	Sell	507,922 -384,179	-43%	-$114M	0.71%	22
2017 Q2	$242M	Buy	892,101 +675,631	+312%	+$179M	1.36%	6
2017 Q1	$59.2M	Buy	216,470 +162,928	+304%	+$46.1M	0.33%	71
2016 Q4	$15.2M	Sell	53,542 -64,006	-54%	-$19M	0.11%	232
2016 Q3	$36.8M	Buy	+117,548	New	+$34.8M	0.26%	105
2016 Q2	–	Sell	-102,200	Closed	-$26.6M	–	726
2016 Q1	$26.6M	Buy	102,200 +15,500	+18%	+$4.09M	0.2%	139
2015 Q4	$26.6M	Buy	86,700 +79,900	+1,175%	+$23M	0.22%	126
2015 Q3	$1.98M	Buy	+6,800	New	+$2.25M	0.02%	563
2015 Q2	–	Sell	-8,800	Closed	-$3.72M	–	720
2015 Q1	$3.72M	Buy	+8,800	New	+$3.47M	0.03%	484
2014 Q3	–	Sell	-7,600	Closed	-$2.4M	–	651
2014 Q2	$2.4M	Buy	+7,600	New	+$2.29M	0.02%	539

Other funds holding BIIB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Point72 Asset Management's BIIB Position: Q1 2026 in Review

Point72 Asset Management reduced its Biogen (BIIB) stake by 71% in Q1 2026, selling an estimated $369M and leaving 809,617 shares worth $148M. The position accounts for 0.19% of the portfolio, ranked #97.

Point72 Asset Management first reported a position in BIIB in Q2 2014 and has held it in 34 quarters since. The position peaked at $543M in Q3 2025. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

Point72 Asset Management held 809,617 shares of Biogen worth $148M as of Q1 2026.
Point72 Asset Management sold 2,003,575 Biogen shares in Q1 2026, an estimated $369M.
Biogen made up 0.19% of Point72 Asset Management's portfolio in Q1 2026, its #97 holding.
Point72 Asset Management first reported a position in Biogen in Q2 2014 and has held it in 34 quarters since.
Point72 Asset Management's Biogen position peaked at $543M in Q3 2025.
1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.